Please login to the form below

Not currently logged in
Email:
Password:

fluticasone furoate

This page shows the latest fluticasone furoate news and features for those working in and with pharma, biotech and healthcare.

Is GSK planning to exit the respiratory business?

Is GSK planning to exit the respiratory business?

Much of its recent success was built on the back of combination therapies that were first introduced in the late 1980s, and culminated in its blockbuster Advair/Seretide (salmeterol/fluticasone propionate) ... GSK has high hopes for three-drug

Latest news

  • AZ prepares to file COPD triple, taking on rival GSK AZ prepares to file COPD triple, taking on rival GSK

    triple – based on LABA vilanterol, LAMA  umeclidinium and ICS fluticasone furoate – in the US and Europe last year.

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    Anoro is one of the drugs GSK is hoping will help replace its COPD blockbuster Seretide/Advair (salmeterol/fluticasone propionate), which has lost patent protection and seen revenues slide in recent ... GSK’s Trelegy (umeclidinium/vilanterol/

  • GSK gets maintenance indication for Trelegy GSK gets maintenance indication for Trelegy

    The new US label means Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) can be used in a broader population of chronic obstructive pulmonary disease (COPD) patients with difficulty breathing or who see ... GSK claims Trelegy has made the

  • AZ’s COPD triple data sets up market clash with GSK AZ’s COPD triple data sets up market clash with GSK

    on LABA vilanterol, LAMA  umeclidinium and ICS fluticasone furoate - in the US and Europe last year. ... salmeterol and fluticasone propionate) that was a $7bn product at its peak but has seen sales slip of late, coming in at $3.3bn in the first nine

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    The EU regulator cleared Trelegy (fluticasone furoate/umeclidinium/vilanterol) - considered to be the most important new product in the company’s ailing respiratory franchise - as a maintenance treatment in adults with ... GSK has been bringing other

More from news
Approximately 5 fully matching, plus 32 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics